InspireMD Q2 revenue beats estimates on international demand

InspireMD

17/08/2026 12:12

Overview
US carotid stent maker's Q2 revenue was flat yr/yr but beat analyst expectations
Q2 net loss and income from operations both beat analyst estimates
Quarter impacted by voluntary U.S. recall; international revenue rose 21%

Outlook
Company expects FDA decisions on CGuard Prime 80 cm and original CGuard platform later this year
InspireMD plans FDA submission for improved CGuard Prime 135 cm delivery system before year-end
Company expects annualized savings of about $9 mln from recent cost-cutting actions

Result Drivers
VOLUNTARY RECALL - Q2 results impacted by voluntary recall of CGuard Prime 135 cm delivery system in U.S., leading to negative U.S. revenue and inventory impairment
INTERNATIONAL DEMAND - 21% growth in international revenue driven by increased demand across most countries
COST SAVINGS INITIATED - Post-quarter cost-saving actions expected to generate annual savings of about $9 mln

Company press release: ID:nGNX7V8h4v

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.77 mln
$1.38 mln (3 Analysts)
Q2 Net Loss
Beat
$14.32 mln
$16.61 mln (3 Analysts)
Q2 Income From Operations
Beat
-$14.45 mln
-$16.75 mln (3 Analysts)
Q2 Gross Loss
 
$774,000
 
Q2 Loss Per Basic Share
 
$0.17
 
Q2 Operating Expenses
 
$13.67 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for InspireMD Inc is $4.00, about 307.2% above its August 14 closing price of $0.98

Reuters Recommended Reads
Aug 14 - Medical device maker Retractable Technologies' Q2 sales drop on weak EasyPoint needle orders
Aug 14 - Milestone Scientific Q2 revenue rises 22% on medical segment growth, reaffirms 2026 outlook
Aug 14 - US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)